Understand the source comparison
Adamax Adamantyl-Modified Neuroprotection: Comparison
The following comparison evaluates adamax adamantyl-modified neuroprotection against other neuroprotective peptide classes and small-molecule agents used in neurological research. Adamax (adamantyl-modified) Passive diffusion; CNS/plasma ratio 0.3–0.6 2.5–4.5
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- The following comparison evaluates adamax adamantyl-modified neuroprotection against other neuroprotective peptide classes and small-molecule agents used in neurological research.
- Adamax (adamantyl-modified)
- Passive diffusion; CNS/plasma ratio 0.3–0.6
- 2.5–4.5 hours
- BDNF/NGF upregulation, NMDA modulation
- Subcutaneous, intranasal
- Preclinical (rodent models)
- Best BBB penetration among peptide classes; practical dosing intervals
- Unmodified neuroprotective peptides
- Poor; requires high-dose peripheral administration or direct CNS injection
- 15–40 minutes
- Neurotrophic signaling, anti-apoptotic pathways
- Intravenous, intracerebroventricular
- Preclinical
- Requires invasive delivery or supraphysiological doses; limited translatability
- Cerebrolysin
- Moderate; mixture contains variable BBB-permeable fractions
- 1–3 hours (variable)
- Multi-target: neurotrophic, anti-glutamatergic, anti-oxidant
- Intravenous
- Clinical (approved in select countries)
- Established clinical data but unclear mechanism; less selective than single-peptide compounds
- Dihexa
- High; orally bioavailable
- 2–5 hours (oral)
- HGF/c-Met pathway activation, synaptogenesis
- Oral, subcutaneous
- Superior oral bioavailability; potent but broader receptor effects raise specificity concerns
- Small-molecule NMDA antagonists (memantine)
- High; passive diffusion
- 60–80 hours
- Non-competitive NMDA antagonism
- Oral
- Clinical (approved for Alzheimer's)
- Long half-life allows once-daily dosing; narrow therapeutic window limits neuroprotection scope
- Semax Amidate Peptide
- Moderate; requires intranasal or frequent dosing
- 30–90 minutes
- Melanocortin receptor modulation, BDNF upregulation
- Intranasal, subcutaneous
- Preclinical and clinical (Russia)
- Effective cognitive enhancer but shorter duration requires multiple daily doses
- Adamax adamantyl-modified neuroprotection occupies a distinct pharmacological niche—it provides peptide-specific receptor targeting with small-molecule-like BBB permeability. The 2.5–4.5 hour half-life enables twice-daily dosing protocols that are practical for chronic studies, unlike unmodified peptides that require continuous infusion or multiple daily injections. Compared to small molecules like memantine, adamax retains the multi-target benefits of peptide signaling (neurotrophic factor upregulation, anti-apoptotic pathways) rather than relying solely on receptor antagonism.
- The primary limitation compared to orally bioavailable compounds like Dihexa is the requirement for parenteral administration—adamantyl modification improves BBB penetration but does not confer oral bioavailability due to first-pass hepatic metabolism and gastrointestinal peptidase degradation. For research applications where invasive administration is acceptable, adamax offers superior receptor selectivity and a well-characterized mechanism compared to peptide mixtures like Cerebrolysin.